Description: Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Home Page: www.natera.com
NTRA Technical Analysis
13011 McCallen Pass Building A
San Carlos,
CA
78753
United States
Phone:
650 249 9090
Officers
Name | Title |
---|---|
Dr. Matthew Rabinowitz Ph.D. | Co-Founder & Exec. Chairman |
Mr. Steven Leonard Chapman | CEO, Pres & Director |
Mr. Michael B. Brophy M.B.A. | Chief Financial Officer |
Mr. Robert A. Schueren | Chief Operating Officer |
Mr. Daniel Rabinowitz L.L.M., LL.M. | Sec. & Chief Legal Officer |
Mr. Jonathan Sheena M.Eng. | Co-Founder & Director |
Ms. Olesya A. Anisimova CPA | Chief Accounting Officer |
Mr. Rishi Kacker | Chief Technology Officer |
Mr. Eric A. Evans | Chief Scientific Officer |
Mr. Phil Grinnell | VP of Sales |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 11.7378 |
Price-to-Sales TTM: | 5.6568 |
IPO Date: | 2015-07-02 |
Fiscal Year End: | December |
Full Time Employees: | 2670 |